90%Confidence
0Views
FDASource
2026-03-10Date
Summary
FDA issues Class II recall for BioGlo Fluorescein Sodium Ophthalmic Strips due to sterility concerns from non-compliance with cGMP. This signals potential supply chain and quality control issues for HUB Pharmaceuticals and manufacturer Omni Lens, impacting patient safety and brand reputation.
Actionable: Monitor HUB Pharmaceuticals for potential stock impact and consider reviewing investments in companies reliant on Omni Lens manufacturing.
AI Confidence: 90%
Data Points
firmWizcure Pharmaa Private Limited
classificationClass II
statusOngoing
distributionDistributed Nationwide in the USA
productBioGlo Fluorescein Sodium Ophthalmic Strips USP, 100 diagnostic strips, Manufactured by Omni Lens PVT. Ltd., 5 - Samrudhhi, Opp. Sakar-III, Navrangpur
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now